Trial Profile
Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2021
Price :
$35
*
At a glance
- Drugs Lovastatin (Primary) ; Vildagliptin (Primary)
- Indications Thyroid cancer
- Focus Biomarker; Pharmacodynamics
- 02 Jul 2021 Status changed from active, no longer recruiting to completed.
- 14 Oct 2018 Planned End Date changed from 1 Jul 2020 to 7 Jul 2020.
- 04 Apr 2018 New trial record